Form 4: TherapeuticsMD Director Gail K. Naughton Reports Stock Transactions
SEC Form 4 Filing
Director Gail K. Naughton reports the acquisition and disposal of TherapeuticsMD, Inc. common stock related to the settlement of restricted stock units.
Summary
- On February 18, 2025, Gail K. Naughton, a director of TherapeuticsMD, Inc., reported a transaction involving the company's common stock.
- Naughton acquired 8,500 shares of common stock upon the settlement of restricted stock units (RSUs).
- The RSUs vested on July 17, 2024, and each RSU represents a contingent right to receive one share of common stock.
- The transaction was reported on February 20, 2025.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the actions of company leadership.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| July 17, 2024 | Restricted Stock Units vested |
| February 18, 2025 | Reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs |
| February 20, 2025 | Date of Form 4 filing |
Keywords
TherapeuticsMD, TXMD, Form 4, Gail K. Naughton, Director, Stock Transaction, Restricted Stock Units, RSU, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.